The prognostic value of YKL-40 concentrations in nonmyeloablative conditioning allogeneic hematopoietic cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 9, 2011, Pages 1299-1307

  Mørup, Anne Mette ^a   Kornblit, Brian ^a   Johansen, Julia S ^a   Masmas, Tania Nicole ^a   Madsen, Hans O ^a   Vindeløv, Lars ^a   Garred, Peter ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Ch13L1; Graft versus host disease; Hematopoietic cell transplantation; Nonmyeloblative conditioning; Prognosis; YKL 40

Indexed keywords

BIOLOGICAL MARKER; PROTEIN; PROTEIN YKL 40; UNCLASSIFIED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ARTICLE; CONTROLLED STUDY; DONOR; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NONMYELOABLATIVE CONDITIONING; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN POLYMORPHISM; RECIPIENT; RELAPSE;

ADIPOKINES; ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; GROWTH SUBSTANCES; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LECTINS; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 80051671998     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.01.008     Document Type: Article

References (43)

1. Kahl C., Storer B.E., Sandmaier B.M., et al. Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. Blood 2007, 110:2744-2748.
2. Sorror M.L., Maris M.B., Storb R., et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005, 106:2912-2919.
3. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110:4606-4613.
4. Pihusch M., Pihusch R., Fraunberger P., et al. Evaluation of C-reactive protein, interleukin-6, and procalcitonin levels in allogeneic hematopoietic stem cell recipients. Eur J Haematol 2006, 76:93-101.
5. Fuji S., Kim S.W., Fukuda T., et al. Preengraftment serum C-reactive protein (CRP) value may predict acute graft-versus-host disease and nonrelapse mortality after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2008, 14:510-517.
6. Schots R., Kaufman L., Van Riet I., et al. Proinflammatory cytokines and their role in the development of major transplant-related complications in the early phase after allogeneic bone marrow transplantation. Leukemia 2003, 17:1150-1156.
7. Min C.K., Lee W.Y., Min D.J., et al. The kinetics of circulating cytokines including IL-6, TNF-alpha, IL-8 and IL-10 following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2001, 28:935-940.
8. Willems E., Humblet-Baron S., Dengis O., Seidel L., Beguin Y., Baron F. Elevations of tumor necrosis factor receptor 1 at day 7 and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Bone Marrow Transplant 2010, 45:1442-1448.
9. Artz A.S., Wickrema A., Dinner S., et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2008, 14:1209-1216.
10. Kanda J., Mizumoto C., Ichinohe T., et al. Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 2010.
11. Johansen J.S., Schultz N.A., Jensen B.V. Plasma YKL-40: a potential new cancer biomarker?. Future Oncol 2009, 5:1065-1082.
12. Johansen J.S., Bojesen S.E., Mylin A.K., Frikke-Schmidt R., Price P.A., Nordestgaard B.G. Elevated plasma YKL-40 predicts increased risk of gastrointestinal cancer and decreased survival after any cancer diagnosis in the general population. J Clin Oncol 2009, 27:572-578.
13. Johansen J.S., Bojesen S.E., Tybjaerg-Hansen A., Mylin A.K., Price P.A., Nordestgaard B.G. Plasma YKL-40 and total and disease-specific mortality in the general population. Clin Chem 2010, 56:1580-1591.
14. Johansen J.S. Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer. Dan Med Bull 2006, 53:172-209.
15. Malinda K.M., Ponce L., Kleinman H.K., Shackelton L.M., Millis A.J. Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells. Exp Cell Res 1999, 250:168-173.
16. Hakala B.E., White C., Recklies A.D. Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993, 268:25803-25810.
17. Dasuri K., Antonovici M., Chen K., et al. The synovial proteome: analysis of fibroblast-like synoviocytes. Arthritis Res Ther 2004, 6:R161-R168.
18. Volck B., Price P.A., Johansen J.S., et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 1998, 110:351-360.
19. Rehli M., Krause S.W., Andreesen R. Molecular characterization of the gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 1997, 43:221-225.
20. Rehli M., Niller H.H., Ammon C., et al. Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 2003, 278:44058-44067.
21. Johansen J.S., Hoyer P.E., Larsen L.A., Price P.A., Mollgard K. YKL-40 protein expression in the early developing human musculoskeletal system. J Histochem Cytochem 2007, 55:1213-1228.
22. Nishikawa K.C., Millis A.J. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res 2003, 287:79-87.
23. Kzhyshkowska J., Mamidi S., Gratchev A., et al. Novel stabilin-1 interacting chitinase-like protein (SI-CLP) is up-regulated in alternatively activated macrophages and secreted via lysosomal pathway. Blood 2006, 107:3221-3228.
24. Dickey B.F. Exoskeletons and exhalation. N Engl J Med 2007, 357:2082-2084.
25. Lee C.G., Hartl D., Lee G.R., et al. Role of breast regression protein 39 (BRP-39)/chitinase 3-like-1 in Th2 and IL-13-induced tissue responses and apoptosis. J Exp Med 2009, 206:1149-1166.
26. Johansen J.S., Stoltenberg M., Hansen M., et al. Serum YKL-40 concentrations in patients with rheumatoid arthritis: relation to disease activity. Rheumatology (Oxford) 1999, 38:618-626.
27. Vind I., Johansen J.S., Price P.A., Munkholm P. Serum YKL-40, a potential new marker of disease activity in patients with inflammatory bowel disease. Scand J Gastroenterol 2003, 38:599-605.
28. Hedegaard A., Sejersten R.R., Johansen J.S., Jorgensen E., Kastrup J. Plasma YKL-40 and recovery of left ventricular function after acute myocardial infarction. Scand J Clin Lab Invest 2010, 70:80-86.
29. Johansen J.S., Krabbe K.S., Moller K., Pedersen B.K. Circulating YKL-40 levels during human endotoxaemia. Clin Exp Immunol 2005, 140:343-348.
30. Kornblit B., Masmas T., Madsen H.O., et al. Haematopoietic cell transplantation with non-myeloablative conditioning in Denmark: disease-specific outcome, complications and hospitalization requirements of the first 100 transplants. Bone Marrow Transplant 2008, 41:851-859.
31. Sullivan K.M. Graft-vs-host disease. Thomas' Hematopoietic Cell Transplantation 2004, 635-664. Blackwell Publishing, Malden, MA. K.G. Blume, S.J. Forman, F.R. Appelbaum (Eds.).
32. Kornblit B., Masmas T., Petersen S.L., et al. Association of HMGB1 polymorphisms with outcome after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 2010, 16:239-252.
33. Hogdall E.V., Johansen J.S., Kjaer S.K., Price P.A., Blaakjaer J., Hogdall C.K. Stability of YKL-40 concentration in blood samples. Scand J Clin Lab Invest 2000, 60:247-251.
34. Lal A., Lash A.E., Altschul S.F., et al. A public database for gene expression in human cancers. Cancer Res 1999, 59:5403-5407.
35. Huang Y., Prasad M., Lemon W.J., et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci U S A 2001, 98:15044-15049.
36. Lau S.H., Sham J.S., Xie D., et al. Clusterin plays an important role in hepatocellular carcinoma metastasis. Oncogene 2006, 25:1242-1250.
37. Shao R., Hamel K., Petersen L., et al. YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 2009, 28:4456-4468.
38. Pelloski C.E., Lin E., Zhang L., et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res 2006, 12:3935-3941.
39. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
40. Zhao X., Tang R., Gao B., et al. Functional variants in the promoter region of Chitinase 3-like 1 (CHI3L1) and susceptibility to schizophrenia. Am J Hum Genet 2007, 80:12-18.
41. Ober C., Tan Z., Sun Y., et al. Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function. N Engl J Med 2008, 358:1682-1691.
42. Berres M.L., Papen S., Pauels K., et al. A functional variation in CHI3L1 is associated with severity of liver fibrosis and YKL-40 serum levels in chronic hepatitis C infection. J Hepatol 2009, 50:370-376.
43. Smigielski E.M., Sirotkin K., Ward M., Sherry S.T. dbSNP: a database of single nucleotide polymorphisms. Nucleic Acids Res 2000, 28:352-355.